E. Alvarez

4.0k total citations
257 papers, 2.7k citations indexed

About

E. Alvarez is a scholar working on Epidemiology, Pathology and Forensic Medicine and Toxicology. According to data from OpenAlex, E. Alvarez has authored 257 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Epidemiology, 40 papers in Pathology and Forensic Medicine and 39 papers in Toxicology. Recurrent topics in E. Alvarez's work include Substance Abuse Treatment and Outcomes (51 papers), Forensic Toxicology and Drug Analysis (38 papers) and Alcohol Consumption and Health Effects (37 papers). E. Alvarez is often cited by papers focused on Substance Abuse Treatment and Outcomes (51 papers), Forensic Toxicology and Drug Analysis (38 papers) and Alcohol Consumption and Health Effects (37 papers). E. Alvarez collaborates with scholars based in Spain, United States and Switzerland. E. Alvarez's co-authors include M C del Río, Inmaculada Fierro, Jennifer S. Brodbelt, Eduardo Tamayo, Francisco Herrera‐Gómez, Arumugam Manthiram, Javier Castrodeza, T. Arunkumar, José I. Gómez-Herreras and Eduardo Gutiérrez‐Abejón and has published in prestigious journals such as The Lancet, Journal of the American Chemical Society and Analytical Chemistry.

In The Last Decade

E. Alvarez

241 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Alvarez Spain 26 713 316 311 269 264 257 2.7k
Alison L Jones United Kingdom 31 563 0.8× 90 0.3× 267 0.9× 488 1.8× 260 1.0× 112 3.9k
Arialdi Miniño United States 35 1.3k 1.8× 123 0.4× 176 0.6× 189 0.7× 424 1.6× 50 5.7k
Edward P. Krenzelok United States 33 174 0.2× 117 0.4× 345 1.1× 438 1.6× 330 1.3× 207 4.1k
Bertrand Yersin Switzerland 33 1.1k 1.6× 389 1.2× 107 0.3× 99 0.4× 474 1.8× 137 3.4k
James A. Feldman United States 32 434 0.6× 109 0.3× 260 0.8× 194 0.7× 549 2.1× 131 5.1k
Jerrold B. Leikin United States 28 196 0.3× 96 0.3× 226 0.7× 275 1.0× 318 1.2× 161 2.6k
Martin Schulz Germany 31 235 0.3× 135 0.4× 466 1.5× 315 1.2× 492 1.9× 155 4.1k
Stephen H. Jackson United Kingdom 29 314 0.4× 106 0.3× 104 0.3× 296 1.1× 414 1.6× 108 4.2k
Rose A. Rudd United States 25 2.1k 2.9× 138 0.4× 510 1.6× 735 2.7× 1.0k 3.8× 31 8.0k
Justine Davies United Kingdom 38 564 0.8× 543 1.7× 31 0.1× 125 0.5× 587 2.2× 182 5.7k

Countries citing papers authored by E. Alvarez

Since Specialization
Citations

This map shows the geographic impact of E. Alvarez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Alvarez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Alvarez more than expected).

Fields of papers citing papers by E. Alvarez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Alvarez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Alvarez. The network helps show where E. Alvarez may publish in the future.

Co-authorship network of co-authors of E. Alvarez

This figure shows the co-authorship network connecting the top 25 collaborators of E. Alvarez. A scholar is included among the top collaborators of E. Alvarez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Alvarez. E. Alvarez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Roncero, Carlos, et al.. (2025). Is there a risk of esketamine misuse in clinical practice?. Therapeutic Advances in Drug Safety. 16. 1591762909–1591762909. 2 indexed citations
3.
4.
5.
Gutiérrez‐Abejón, Eduardo, et al.. (2022). Non-Adherence to Antidepressant Treatment and Related Factors in a Region of Spain: A Population-Based Registry Study. Pharmaceutics. 14(12). 2696–2696. 15 indexed citations
6.
Martín-Fernández, Marta, E. Alvarez, Christian Ortega‐Loubon, et al.. (2021). Predictive Modeling of Poor Outcome in Severe COVID-19: A Single-Center Observational Study Based on Clinical, Cytokine and Laboratory Profiles. Journal of Clinical Medicine. 10(22). 5431–5431. 6 indexed citations
7.
Tamayo-Velasco, Álvaro, E. Alvarez, Hugo Gonzalo‐Benito, et al.. (2021). Evaluation of Cytokines as Robust Diagnostic Biomarkers for COVID-19 Detection. Journal of Personalized Medicine. 11(7). 681–681. 15 indexed citations
8.
Tamayo-Velasco, Álvaro, Pedro Martínez-Paz, Ignacio de la Fuente, et al.. (2021). HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients. Journal of Clinical Medicine. 10(9). 2017–2017. 37 indexed citations
9.
Gutiérrez‐Abejón, Eduardo, et al.. (2021). A Population-Based Registry Analysis on Hospitalized COVID-19 Patients with Previous Cardiovascular Disease: Clinical Profile, Treatment, and Predictors of Death. Journal of Cardiovascular Development and Disease. 8(12). 167–167. 1 indexed citations
10.
Gutiérrez‐Abejón, Eduardo, Francisco Herrera‐Gómez, & E. Alvarez. (2021). Trends in the use of antihistamines with reference to drivers between 2015 and 2019: A population‐based registry analysis. Fundamental and Clinical Pharmacology. 35(6). 1168–1178. 6 indexed citations
11.
Gutiérrez‐Abejón, Eduardo, et al.. (2020). Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals. International Journal of Environmental Research and Public Health. 17(24). 9360–9360. 9 indexed citations
12.
13.
Gutiérrez‐Abejón, Eduardo, et al.. (2020). Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving. Pharmaceuticals. 13(8). 165–165. 4 indexed citations
14.
Gutiérrez‐Abejón, Eduardo, et al.. (2020). Trends in Antidepressants Use in Spain between 2015 and 2018: Analyses from a Population-Based Registry Study with Reference to Driving. Pharmaceuticals. 13(4). 61–61. 11 indexed citations
15.
Chehade, Hassib, Yannick D. Müller, Julien Vionnet, et al.. (2020). The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies. Biomedicines. 8(9). 355–355. 11 indexed citations
16.
Herrera‐Gómez, Francisco, et al.. (2019). Drivers who tested positive for cannabis in oral fluid: a longitudinal analysis of administrative data for Spain between 2011 and 2016. BMJ Open. 9(8). e026648–e026648. 9 indexed citations
17.
Herrera‐Gómez, Francisco, Juan Bustamante‐Munguira, É. Alamartine, et al.. (2019). Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses. Scientific Reports. 9(1). 8951–8951. 15 indexed citations
18.
Ortega‐Loubon, Christian, Francisco Herrera‐Gómez, Pablo Jorge-Monjas, et al.. (2019). Near-Infrared Spectroscopy Monitoring in Cardiac and Noncardiac Surgery: Pairwise and Network Meta-Analyses. Journal of Clinical Medicine. 8(12). 2208–2208. 30 indexed citations
19.
Herrera‐Gómez, Francisco, et al.. (2018). Correction of Hyponatremia May Be a Treatment Stratification Biomarker: A Two-Stage Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 7(9). 262–262. 5 indexed citations
20.
Alvarez, E., et al.. (1991). Illegal drugs and driving in Spain. Medical science research. 19(15). 491–492. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alison L Jones Breakdown of academic impact, for papers by Arialdi Miniño Breakdown of academic impact, for papers by Edward P. Krenzelok Breakdown of academic impact, for papers by Bertrand Yersin Breakdown of academic impact, for papers by James A. Feldman Breakdown of academic impact, for papers by Jerrold B. Leikin Breakdown of academic impact, for papers by Martin Schulz Breakdown of academic impact, for papers by Stephen H. Jackson Breakdown of academic impact, for papers by Rose A. Rudd Breakdown of academic impact, for papers by Justine Davies
Rankless by CCL
2026